Inhibikase Therapeutics (IKT) Net Margin (QoQ) (2020 - 2023)

Inhibikase Therapeutics (IKT) Net Margin (QoQ) (2020 - 2023) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Inhibikase Therapeutics 407.51 Mn 237.14 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 -44.04 Bn
Sep 30, 2023 -67,103.00
Jun 30, 2023 202,172.00
Mar 31, 2023 -56,499.00
Dec 31, 2022 5.58 Mn
Sep 30, 2022 820,761.00
Jun 30, 2022 -6.07 Mn
Mar 31, 2022 24.83 Mn
Dec 31, 2021 -25.70 Mn
Sep 30, 2021 -116,786.00
Jun 30, 2021 -600.00
Mar 31, 2021 52,144.00
Dec 31, 2020 107,088.00
Sep 30, 2020 -158,760.00
Jun 30, 2020 1,005.00